Voyageur Pharmaceuticals Ltd. (TSX-V: VM) (OTC Pink: VYYRF) is evaluating three potential locations in the United States for its planned integrated iodine and barium contrast drug manufacturing facility, the company announced June 18, 2026. The Canadian developer of pharmaceutical-grade contrast media is conducting a comprehensive technical, regulatory, economic, and logistical analysis of candidate sites, with a focus on proximity to iodine brine sources, infrastructure, skilled labor, and government incentives.
Strong candidate locations have been identified in Oklahoma and Texas, offering proximity to Voyageur’s iodine extraction initiatives in Oklahoma’s Anadarko Basin, robust transportation infrastructure, access to skilled labor and municipal water, and a competitive business climate. The company is actively engaging with economic development authorities across multiple U.S. jurisdictions, and the final site will be selected based on the most attractive overall package, with a strong emphasis on incentive and support packages.
The planned facility will receive concentrated iodine liquor from Voyageur’s proprietary closed-loop Streamlined Iodine Process directly from its Oklahoma brine operations, along with high-purity barite from the Frances Creek project. This integrated GMP campus will combine on-site iodine-to-API synthesis with barite upgrading into USP-grade material and sterile injectable manufacturing, delivering what Voyageur believes will be the first fully domestic, vertically integrated supply chain for both iodinated and barium contrast agents at materially lower cost.
Key anticipated project highlights include cost leadership through vertical integration, significant opportunities for U.S. federal and state funding and incentives, creation of 150–250 direct high-skilled jobs, and substantial annual economic activity and tax revenue. The facility is expected to enhance supply chain security by enabling efficient management of iodine and barium contrast production, while supporting Voyageur’s collaboration with Bayer on the Oklahoma iodine prill project.
Brent Willis, CEO of Voyageur Pharmaceuticals, stated: “This location decision optimizes logistics between our Oklahoma iodine sources and Canadian barite resources while providing the infrastructure required for GMP-compliant manufacturing. We are evaluating multiple strong jurisdictions and will select the site that delivers the most compelling overall package, including the strongest incentive support.”
Site preparation and detailed engineering are targeted to commence in late 2026, with first production expected in Q4 2028–2029, subject to financing, regulatory approvals, and other conditions. This announcement builds on Voyageur’s ongoing collaboration with Bayer and advancements in its barium contrast portfolio, including Health Canada-approved products already in commercial use. The company continues to work with economic development corporations and state/federal partners to advance incentives and permitting. Management believes the project aligns with U.S. priorities for domestic critical and strategic minerals, pharmaceutical onshoring, and rural economic development.
For more information, visit https://voyageurpharmaceuticals.ca.
